Öz
Amaç
Osteoporoz, dünya çapında genetik faktörlerin önemli ölçüde katkıda bulunduğu ciddi bir metabolik kemik hastalığıdır. Menopoz sonrası osteoporotik ve menopoz sonrası sağlıklı Kuzey Hindistanlı kadınlarda 5-HTT değişken sayılı tandem tekrarları (5HTTVNTR) ve serotonin taşıyıcı geni 5-hidroksi triptamin taşıyıcı bağlantılı polimorfik bölge veya serotonin taşıyıcı bağlantılı promotör bölgesi (5HTTLPR) polimorfizmlerini, serum seviyelerini ve kemik mineral yoğunluğunu (KMY) araştırdık.
Gereç ve Yöntem
Bu çalışmaya 165 menopoz sonrası osteoporotik (yaş 54,44±6,00) ve 165 menopoz sonrası sağlıklı Kuzey Hindistanlı kadın (yaş 54,47±6,46) dahil edildi. Farklı iskelet bölgelerinin KMY’leri çift enerjili X-ışını absorpsiyometrisi ile ölçüldü. Serotonin serum seviyesi enzim bağlantılı immünosorbent testi ile değerlendirildi ve genotipleme polimeraz zincir reaksiyonu yöntemi kullanılarak yapıldı.
Bulgular
Bu çalışma, hasta grubunda, 5HTTVNTR polimorfizminin homozigot mutant 12/12 genotipine sahip deneklerin femur boynunda anlamlı derecede daha düşük KMY ve buna eşlik eden serotonin seviyelerinin azaldığını göstermiştir. Benzer şekilde, 5HTTLPR varyantının LL genotipine sahip deneklerde, hem lomber omurgada hem de femur boynunda anlamlı derecede düşük KMY ve daha düşük serotonin seviyeleri gözlenmiştir. Kontrol grubunda, her iki polimorfizmin serum seviyelerinin anlamlı derecede düşük olduğu bulunmuştur. Homozigot mutant 12/12 5HTTVNTR genotipinde anlamlı derecede düşük KMY bulunmazken, 5HTTLPR LL genotipinde femur boynunda anlamlı KMY düşüşü gözlenmiştir. Ayrıca, hastalar ve kontroller arasında serotonin genotipleri ve alellerinin sıklığında anlamlı bir fark gözlenmemiştir.
Sonuç
Bu bulgular, serotonin gen polimorfizmlerinin BMD’deki varyasyonlarla ilişkili olabileceğini ve Kuzey Hindistan’daki postmenopozal kadınlarda osteoporoz gelişimine katkıda bulunabileceğini düşündürmektedir.
Anahtar Kelimeler:
Osteoporoz, serotonin taşıyıcı gen, postmenopozal kadın, BMD, genotip
Kaynaklar
1NIH consensus development panel on osteoporosis prevention, diagnosis, and therapy. Osteoporosis prevention, diagnosis, and therapy. JAMA. 2001;285:785-95.
2Ammann P, Rizzoli R. Bone strength and its determinants. Osteoporos Int. 2003;14(Suppl 3):S13-8.
3Eisman JA. Genetics of osteoporosis. Endocr Rev. 1999;20:788-804.
4Ralston SH. Genetic control of susceptibility to osteoporosis. J Clin Endocrinol Metab. 2002;87:2460-6.
5Kanis JA, Odén A, McCloskey EV, Johansson H, Wahl DA, Cooper C, et al. A systematic review of hip fracture incidence and probability of fracture worldwide. Osteoporos Int. 2012;23:2239-56.
6Mithal A, Kaur P. Osteoporosis in Asia: a call to action. Curr Osteoporos Rep. 2012;10:245-7.
7Lesch KP, Balling U, Gross J, Strauss K, Wolozin BL, Murphy DL, et al. Organization of the human serotonin transporter gene. J Neural Transm Gen Sect. 1994;95:157-62.
8Wang YM, Chang Y, Chang YY, Cheng J, Li J, Wang T, et al. Serotonin transporter gene promoter region polymorphisms and serotonin transporter expression in the colonic mucosa of irritable bowel syndrome patients. Neurogastroenterol Motil. 2012;24:560-5, e254-5.
9Park JM, Choi MG, Park JA, Oh JH, Cho YK, Lee IS, et al. Serotonin transporter gene polymorphism and irritable bowel syndrome. Neurogastroenterol Motil. 2006;18:995-1000.
10Areeshi MY, Haque S, Panda AK, Mandal RK. A serotonin transporter gene (SLC6A4) polymorphism is associated with reduced risk of irritable bowel syndrome in American and Asian population: a meta-analysis. PLoS One. 2013;8:e75567.
11MacKenzie A, Quinn J. A serotonin transporter gene intron 2 polymorphic region, correlated with affective disorders, has allele-dependent differential enhancer-like properties in the mouse embryo. Proc Natl Acad Sci U S A. 1999;96:15251-5.
12Ferreira JT, Levy PQ, Marinho CR, Bicho MP, Mascarenhas MR. Association of serotonin transporter gene polymorphism 5HTTVNTR with osteoporosis. Acta Reumatol Port. 2011;36:14-9.
13Porcelli S, Fabbri C, Serretti A. Meta-analysis of serotonin transporter gene promoter polymorphism (5-HTTLPR) association with antidepressant efficacy. Eur Neuropsychopharmacol. 2012;22:239-58.
14Serretti A, Kato M, De Ronchi D, Kinoshita T. Meta-analysis of serotonin transporter gene promoter polymorphism (5-HTTLPR) association with selective serotonin reuptake inhibitor efficacy in depressed patients. Mol Psychiatry. 2007;12:247-57.
15Smits KM, Smits LJ, Schouten JS, Stelma FF, Nelemans P, Prins MH. Influence of SERTPR and STin2 in the serotonin transporter gene on the effect of selective serotonin reuptake inhibitors in depression: a systematic review. Mol Psychiatry. 2004;9:433-41.
16Calarge CA, Ellingrod VL, Zimmerman B, Bliziotes MM, Schlechte JA. Variants of the serotonin transporter gene, selective serotonin reuptake inhibitors, and bone mineral density in risperidone-treated boys: a reanalysis of data from a cross-sectional study with emphasis on pharmacogenetics. J Clin Psychiatry. 2011;72:1685-90.
17Lapid MI, Kung S, Frye MA, Biernacka JM, Geske JR, Drake MT, et al. Association of the serotonin transporter-linked polymorphic region genotype with lower bone mineral density. Transl Psychiatry. 2017;7:e1213.
18Yadav VK, Balaji S, Suresh PS, Liu XS, Lu X, Li Z, et al. Pharmacological inhibition of gut-derived serotonin synthesis is a potential bone anabolic treatment for osteoporosis. Nat Med. 2010;16:308-12.
19Yadav VK, Ryu JH, Suda N, Tanaka KF, Gingrich JA, Schütz G, et al. Lrp5 controls bone formation by inhibiting serotonin synthesis in the duodenum. Cell. 2008;135:825-37.
20Gustafsson BI, Westbroek I, Waarsing JH, Waldum H, Solligård E, Brunsvik A, et al. Long-term serotonin administration leads to higher bone mineral density, affects bone architecture, and leads to higher femoral bone stiffness in rats. J Cell Biochem. 2006;97:1283-91.
21Wang Q, Chen D, Nicholson P, Cheng S, Alen M, Mao L, et al. The associations of serum serotonin with bone traits are age- and gender-specific. PLoS One. 2014;9:e109028.
22Wei QS, Chen ZQ, Tan X, Kang LC, Jiang XB, Liang J, et al. Serum serotonin concentration associated with bone mineral density in Chinese postmenopausal women. Scand J Clin Lab Invest. 2017;77:40-4.
23Mödder UI, Achenbach SJ, Amin S, Riggs BL, Melton LJ, Khosla S. Relation of serum serotonin levels to bone density and structural parameters in women. J Bone Miner Res. 2010;25:415-22.
24Kim MK, Kwon HS, Song KH, Kang MI, Baek KH. The relationship of serum serotonin levels to the rate of bone loss and fractures in men. J Clin Densitom. 2018;21:35-40.
25Zhang W, Drake MT. Potential role for therapies targeting DKK1, LRP5, and serotonin in the treatment of osteoporosis. Curr Osteoporos Rep. 2012;10:93-100.
26Garfield LD, Müller DJ, Kennedy JL, Mulsant BH, Reynolds CF, Teitelbaum SL, et al. Genetic variation in the serotonin transporter and HTR1B receptor predicts reduced bone formation during serotonin reuptake inhibitor treatment in older adults. World J Biol Psychiatry. 2014;15:404-10.
